Recommended composition of influenza virus vaccines for use in the 2024 southern hemisphere influenza season
WHO convenes technical consultations in February and September each year to recommend viruses for inclusion in influenza vaccines for the northern hemisphere (NH) and southern hemisphere (SH) influenza seasons, respectively.
Vaccine Monitoring Platform research agenda
The Vaccine Monitoring Platform (VMP) is a collaboration between EMA and ECDC for the timely generation of independent real-world evidence (RWE) on the safety and effectiveness of vaccines in use in EU/EEA immunisation programs.
Is influenza B/Yamagata extinct and what public health implications could this have? An updated literature review and comprehensive assessment of global surveillance databases
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
|
9th Influenza Conference 2023
The Influenza B/Yamagata lineage appears to become extinct: implications for quadrivalent influenza vaccines?
SPI08 session from #ESWI2023
International scientific community gathers in Valencia for the 9th ESWI Conference on Influenza, COVID-19, and RSV
Since it was established 30 years ago, the European Scientific Working Group on Influenza and other Acute Respiratory Viruses (ESWI) is hosting the 9TH ESWI Influenza Conference
SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters
Two doses of COVID-19 mRNA vaccines in the primary series and a booster dose induce a strong antibody response, however, this response can be weak in people older than 80 years.
Viruses - a major cause of amyloid deposition in the brain
Clinically, Alzheimer's disease (AD) is a syndrome with a spectrum of various cognitive disorders.
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.
News
Policy & Recommendations
The role of EU manufacturing capacity in future health crisis
A study assessing scientific, engineering, legal and economic considerations of flexible EU manufacturing and innovation of medical countermeasures for serious cross-border threats to health
News
Policy & Recommendations
European Commission authorises first vaccine to protect older adults from RSV infection
The EC has authorised Arexvy, the first vaccine to protect adults aged 60 years and older, against RSV. This decision marks an important step and has been particularly awaited in light of the increased RSV infections in the EU last winter.
